The head of the board of the European Medicines Agency (EMA) Christa Virtumer-Gohe said that the EMA did not receive data on people vaccinated with the Russian drug Sputnik V.
The European Medicines Agency (EMA) urged EU countries not to rush to approve the Russian Sputnik V coronavirus vaccine. The head of the EMA board Krista Virtumer-Gohe told about this in an interview with the Austrian TV channel ORF.
The EMA said that agency reviews of the drug have not yet been completed, for approval inthe Sputnik V tax is not enough data.
Virtumer-Gohe said that information about the vaccine comes from its manufacturers and it will be tested in accordance with European quality and safety standards.
Sputnik V vaccine was registered in Russia on August 11 last year. Russian President Vladimir Putin argued that it is effective, forms a stable immunity and has passed all the tests.
The vaccine has received criticism in the scientific community, as it was registered before the third phase of clinical trials. In Russia, they announced 95 percent efficiency… International magazine The Lancet wrote about efficiency at 91.6%.
At the same time, a number of Russian scientists noted that the accelerated approach to vaccine registration is contrary to scientific and ethical standards for drug development… Vaccinated Russians have complained of various side effects – fever, loss of smell, high blood pressure.
The Sputnik V vaccine has not been approved in the European Union. In Russia, mass vaccination with a domestic drug is underway, it was also approved, according to data manufacturer, in Argentina, Bolivia, Serbia, Algeria, Palestine, Venezuela, Paraguay and several other countries.
European Commission President Ursula von der Leyen, speaking in Brussels on 17 February, expressed surprise that Russia offers Sputnik V to other countrieswithout vaccinating their own population. The European Commission announced in early March that does not negotiate the purchase of the Sputnik V vaccinedespite the fact that the EU regulator began to consider it for possible approval.
– .
